Use of Laboratory Decision System as a Test Utilization Management Tool in Clinical Settings, Current and Future Perspectives

L Leblow, T. Hamill, Beqaj Sh
{"title":"Use of Laboratory Decision System as a Test Utilization Management Tool in Clinical Settings, Current and Future Perspectives","authors":"L Leblow, T. Hamill, Beqaj Sh","doi":"10.16966/2572-9578.128","DOIUrl":null,"url":null,"abstract":"Managing laboratory test utilization has been a growing problem for the healthcare industry for a long time. With an ever-increasing number of tests, especially in the area of molecular genetics where per test costs are very high, inappropriate utilization is creating a financial burden on healthcare overall. Several large healthcare institutions have made efforts to solve this problem and have developed their own test utilization management approaches. These include, physician education, providing test pricing information, utilizing reminders in Computerized Provider Order Entry (CPOE) systems and/or setting up committees to authorize the use of expensive or complex tests. While these approaches have achieved some minor success in curbing test overutilization and generating cost savings, a robust automated Clinical Laboratory Decision Support System has still been sorely lacking. We present, here, a newly developed Laboratory Decision System, LDSTM as a potential method to address test utilization management in clinical settings. A study of provider and payer use of LDSTM revealed significant improvements in test ordering and management on both sides: a significant reduction in unnecessary tests from the provider’s side and measurable improvement in medical necessity checks from the payer’s side. methods for reducing wasteful testing. A study published by the American College of Physicians (ACP), in 2012, stemming the Tide of over treatment in U.S. Healthcare, explains “the impact of unnecessary tests on healthcare cost totals up to $250 billion a year” [4]. Timely, relevant and actionable data is needed for doctors to accurately order tests, and for labs and other rendering providers to deliver services efficiently and get paid in a timely manner. Further, the rapid growth in molecular and genetic testing (welcomed new tools for diagnosis and disease management) poses a challenge for both healthcare providers and for commercial payers regarding proper utilization of these specialized tests. Given their relatively high cost, inappropriate use of these tests represents an additional financial burden on an already over-taxed healthcare system [2,4,5]. Since laboratory testing provides 70-85% of the objective data upon which physicians base their diagnoses and treatments, laboratory diagnostics has become the single highest-volume medical activity in the U.S., with an estimated 4-5 billion tests performed annually [5]. Inappropriate testing consists of both overand underutilization, which together can dramatically increase healthcare costs. Overutilization refers to tests that are ordered when not clinically indicated, while underutilization refers to tests that are clinically indicated but not ordered. A Harvard Medical School 15Introduction Currently, physicians are challenged by a lack of access to centralized information regarding thousands of available clinical laboratory tests [1]. A study conducted by the Common wealth Fund Survey of Public Views of the U.S. Health Care System showed that over 23% of tests ordered by physicians had previously been performed. Such duplication increases the cost of care while further delaying or confusing the patient’s diagnosis and care [1,2]. Physician uncertainty related to appropriate laboratory utilization was studied by the Center for Disease Control (CDC) in 2011. The study surveyed 1,768 primary care physicians in the U.S and demonstrated that 14.7% had uncertainty in selecting and ordering the correct test and 8.3% had difficulty interpreting tests [3]. When these statistics are applied to over 300 million patient laboratory visits a year in the U.S, inappropriate test ordering and interpretation potentially impacts 23 million patients annually [3]. Such inappropriate test utilization has further downstream clinical and cost impact on our overall healthcare system. The survey also indicated that more than three-quarters of physician respondents indicated that consulting an expert, checking e-references or specialist referrals was helpful in reducing uncertainty in ordering and interpreting lab tests [3]. For these and other compelling reasons, payers, particularly Medicare, are beginning to require standardization of practices and Sci Forschen O p e n H U B f o r S c i e n t i f i c R e s e a r c h Citation: Leblow L, Hamill T, Beqaj SH (2019) Use of Laboratory Decision System as a Test Utilization Management Tool in Clinical Settings, Current and Future Perspectives. J Clin Lab Med 4(1): dx.doi.org/10.16966/2572-9578.128 2 Journal of Clinical and Laboratory Medicine Open Access Journal year meta-analysis indicated that overutilization and underutilization of laboratory tests occurs 20.6% and 44.8% of the time respectively [6]. Inappropriate testing may lead to incorrect or delayed diagnoses and treatments, which negatively impact patient recovery time and associated costs. Test overutilization often increases the likelihood of false-positive results which can result in incorrect diagnoses, additional inappropriate testing, increased costs, and adverse outcomes due to unwarranted intervention [6,7]. Additionally, a consequence of ordering tests which are not indicated often can be the failure to order tests which are clinically ‘indicated’, further compounding the problem. Test underutilization can contribute to an increase in morbidity due to delayed or missed diagnoses and, paradoxically, can lead to downstream overutilization, again resulting in higher costs and poorer patient care [2,7]. With industry and governmental shifts from traditional fee-forservice to value-based care, over/underutilization is a critical issue that affects the bottom line with respect to increased costs and poor clinical outcomes. In order to meet the goals of modern healthcare, medical providers and insurance payers are searching for solutions that will help in making optimal decisions in the selection of diagnostic tests and ensuring the appropriate utilization of laboratory resources. Current Approach to Test Utilization Problem There have been several efforts by large healthcare institutions to counter test utilization problems. However, it is worth listing the main factors influencing ordering behavior: ease of ordering in CPOE, ignorance of test characteristics, peer or supervisor pressure to be extremely thorough, fear of litigation, impatience, desire for certainty of diagnosis, financial incentives, and patient demand [2,5,8,9]. In general, the overall management of these factors requires new tools, education, changes in habits and reward feedback loops [8,10-12]. Two important studies that have attempted to analyze and solve the problem of test utilization are the Veterans Affairs Hospital study [13] and the Massachusetts General Hospital (MGH) study [8,14]. The Veterans Affairs Hospital study managed test utilization by implementing a modified and improved laboratory information system that allowed them to setup special rules, restrictions, reminders and notifications, which lead to reduction in unnecessary tests and decreased cost [13]. The MGH study developed a laboratory utilization management program that required committee review and approval for test orders and acted as a ‘governor’ against practitioners ordering ‘inappropriate’ tests. This method is predictably costly as it necessitates the ‘handson’ participation of expensive experts including pathologists and genetic counselors in decision making and does not result in timely responses [2,5,8,14]. Over burdened clinicians cannot afford to spend large amounts of time tracking down a pathologist for an answer that they often require immediately. Several other studies have used similar strategies to reduce unnecessary test ordering and cost reduction, especially with respect to sending out tests which are often poorly reimbursed, and, therefore, create financial burdens for many small and large hospitals [8,15,16]. Future Approach to Test Utilization Problem Clinical decision support system Selecting appropriate medical tests is an ongoing and growing problem in many specialties including radiology, cardiology, Pulmonology and pharmacology. Since radiology diagnostic imaging is more costly than laboratory testing, the U.S. government has approved a reimbursement reward system for insurance providers that utilize a Clinical Decision Support System (CDSS) to improve imaging utilization and, thereby, decrease unnecessary orders and cost [15]. For example, there is a 2015 “Advanced Imaging Bill” which mandates that government-approved imaging services will only be reimbursed if the insurance claim confirms that appropriate-use criteria was consulted or a CDSS was used [17,18]. The Bill also recommends use of CDSS for other diagnostic test ordering, if available. Accordingly, CDSS’s are currently available for cardiology, medication management, oncology and urology. These developments strongly indicate that there also is a substantial need for a laboratory CDSS to aid healthcare providers in selecting and ordering laboratory tests and reducing inappropriate testing [11,12]. Currently, there are some partially developed and semi-manual lab CDSS’s that help physicians order laboratory tests; however, these modules are provider-driven and require inconvenient interactive user questions to access the information needed [911,19,20]. In addition, these systems do not provide any scoring system for tests based on medical evidence, clinical relevancy and medical necessity as used by radiology CDSS’s. Laboratory decision support system To address these challenges, Medical Database, Inc (MDB) has developed a laboratory decision support platform that includes an easy-to-use test ordering and utilization management application, also known as the Laboratory Decision System or LDSTM. This platform gives healthcare providers access to a systematic and in-depth resource to assist in selecting and ordering the most appropriate laboratory te","PeriodicalId":92069,"journal":{"name":"Journal of clinical and laboratory medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical and laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.16966/2572-9578.128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Managing laboratory test utilization has been a growing problem for the healthcare industry for a long time. With an ever-increasing number of tests, especially in the area of molecular genetics where per test costs are very high, inappropriate utilization is creating a financial burden on healthcare overall. Several large healthcare institutions have made efforts to solve this problem and have developed their own test utilization management approaches. These include, physician education, providing test pricing information, utilizing reminders in Computerized Provider Order Entry (CPOE) systems and/or setting up committees to authorize the use of expensive or complex tests. While these approaches have achieved some minor success in curbing test overutilization and generating cost savings, a robust automated Clinical Laboratory Decision Support System has still been sorely lacking. We present, here, a newly developed Laboratory Decision System, LDSTM as a potential method to address test utilization management in clinical settings. A study of provider and payer use of LDSTM revealed significant improvements in test ordering and management on both sides: a significant reduction in unnecessary tests from the provider’s side and measurable improvement in medical necessity checks from the payer’s side. methods for reducing wasteful testing. A study published by the American College of Physicians (ACP), in 2012, stemming the Tide of over treatment in U.S. Healthcare, explains “the impact of unnecessary tests on healthcare cost totals up to $250 billion a year” [4]. Timely, relevant and actionable data is needed for doctors to accurately order tests, and for labs and other rendering providers to deliver services efficiently and get paid in a timely manner. Further, the rapid growth in molecular and genetic testing (welcomed new tools for diagnosis and disease management) poses a challenge for both healthcare providers and for commercial payers regarding proper utilization of these specialized tests. Given their relatively high cost, inappropriate use of these tests represents an additional financial burden on an already over-taxed healthcare system [2,4,5]. Since laboratory testing provides 70-85% of the objective data upon which physicians base their diagnoses and treatments, laboratory diagnostics has become the single highest-volume medical activity in the U.S., with an estimated 4-5 billion tests performed annually [5]. Inappropriate testing consists of both overand underutilization, which together can dramatically increase healthcare costs. Overutilization refers to tests that are ordered when not clinically indicated, while underutilization refers to tests that are clinically indicated but not ordered. A Harvard Medical School 15Introduction Currently, physicians are challenged by a lack of access to centralized information regarding thousands of available clinical laboratory tests [1]. A study conducted by the Common wealth Fund Survey of Public Views of the U.S. Health Care System showed that over 23% of tests ordered by physicians had previously been performed. Such duplication increases the cost of care while further delaying or confusing the patient’s diagnosis and care [1,2]. Physician uncertainty related to appropriate laboratory utilization was studied by the Center for Disease Control (CDC) in 2011. The study surveyed 1,768 primary care physicians in the U.S and demonstrated that 14.7% had uncertainty in selecting and ordering the correct test and 8.3% had difficulty interpreting tests [3]. When these statistics are applied to over 300 million patient laboratory visits a year in the U.S, inappropriate test ordering and interpretation potentially impacts 23 million patients annually [3]. Such inappropriate test utilization has further downstream clinical and cost impact on our overall healthcare system. The survey also indicated that more than three-quarters of physician respondents indicated that consulting an expert, checking e-references or specialist referrals was helpful in reducing uncertainty in ordering and interpreting lab tests [3]. For these and other compelling reasons, payers, particularly Medicare, are beginning to require standardization of practices and Sci Forschen O p e n H U B f o r S c i e n t i f i c R e s e a r c h Citation: Leblow L, Hamill T, Beqaj SH (2019) Use of Laboratory Decision System as a Test Utilization Management Tool in Clinical Settings, Current and Future Perspectives. J Clin Lab Med 4(1): dx.doi.org/10.16966/2572-9578.128 2 Journal of Clinical and Laboratory Medicine Open Access Journal year meta-analysis indicated that overutilization and underutilization of laboratory tests occurs 20.6% and 44.8% of the time respectively [6]. Inappropriate testing may lead to incorrect or delayed diagnoses and treatments, which negatively impact patient recovery time and associated costs. Test overutilization often increases the likelihood of false-positive results which can result in incorrect diagnoses, additional inappropriate testing, increased costs, and adverse outcomes due to unwarranted intervention [6,7]. Additionally, a consequence of ordering tests which are not indicated often can be the failure to order tests which are clinically ‘indicated’, further compounding the problem. Test underutilization can contribute to an increase in morbidity due to delayed or missed diagnoses and, paradoxically, can lead to downstream overutilization, again resulting in higher costs and poorer patient care [2,7]. With industry and governmental shifts from traditional fee-forservice to value-based care, over/underutilization is a critical issue that affects the bottom line with respect to increased costs and poor clinical outcomes. In order to meet the goals of modern healthcare, medical providers and insurance payers are searching for solutions that will help in making optimal decisions in the selection of diagnostic tests and ensuring the appropriate utilization of laboratory resources. Current Approach to Test Utilization Problem There have been several efforts by large healthcare institutions to counter test utilization problems. However, it is worth listing the main factors influencing ordering behavior: ease of ordering in CPOE, ignorance of test characteristics, peer or supervisor pressure to be extremely thorough, fear of litigation, impatience, desire for certainty of diagnosis, financial incentives, and patient demand [2,5,8,9]. In general, the overall management of these factors requires new tools, education, changes in habits and reward feedback loops [8,10-12]. Two important studies that have attempted to analyze and solve the problem of test utilization are the Veterans Affairs Hospital study [13] and the Massachusetts General Hospital (MGH) study [8,14]. The Veterans Affairs Hospital study managed test utilization by implementing a modified and improved laboratory information system that allowed them to setup special rules, restrictions, reminders and notifications, which lead to reduction in unnecessary tests and decreased cost [13]. The MGH study developed a laboratory utilization management program that required committee review and approval for test orders and acted as a ‘governor’ against practitioners ordering ‘inappropriate’ tests. This method is predictably costly as it necessitates the ‘handson’ participation of expensive experts including pathologists and genetic counselors in decision making and does not result in timely responses [2,5,8,14]. Over burdened clinicians cannot afford to spend large amounts of time tracking down a pathologist for an answer that they often require immediately. Several other studies have used similar strategies to reduce unnecessary test ordering and cost reduction, especially with respect to sending out tests which are often poorly reimbursed, and, therefore, create financial burdens for many small and large hospitals [8,15,16]. Future Approach to Test Utilization Problem Clinical decision support system Selecting appropriate medical tests is an ongoing and growing problem in many specialties including radiology, cardiology, Pulmonology and pharmacology. Since radiology diagnostic imaging is more costly than laboratory testing, the U.S. government has approved a reimbursement reward system for insurance providers that utilize a Clinical Decision Support System (CDSS) to improve imaging utilization and, thereby, decrease unnecessary orders and cost [15]. For example, there is a 2015 “Advanced Imaging Bill” which mandates that government-approved imaging services will only be reimbursed if the insurance claim confirms that appropriate-use criteria was consulted or a CDSS was used [17,18]. The Bill also recommends use of CDSS for other diagnostic test ordering, if available. Accordingly, CDSS’s are currently available for cardiology, medication management, oncology and urology. These developments strongly indicate that there also is a substantial need for a laboratory CDSS to aid healthcare providers in selecting and ordering laboratory tests and reducing inappropriate testing [11,12]. Currently, there are some partially developed and semi-manual lab CDSS’s that help physicians order laboratory tests; however, these modules are provider-driven and require inconvenient interactive user questions to access the information needed [911,19,20]. In addition, these systems do not provide any scoring system for tests based on medical evidence, clinical relevancy and medical necessity as used by radiology CDSS’s. Laboratory decision support system To address these challenges, Medical Database, Inc (MDB) has developed a laboratory decision support platform that includes an easy-to-use test ordering and utilization management application, also known as the Laboratory Decision System or LDSTM. This platform gives healthcare providers access to a systematic and in-depth resource to assist in selecting and ordering the most appropriate laboratory te
使用实验室决策系统作为测试利用管理工具在临床设置,目前和未来的前景
长期以来,管理实验室测试的使用一直是医疗保健行业面临的一个日益严重的问题。随着检测数量的不断增加,特别是在每次检测成本非常高的分子遗传学领域,不适当的利用正在给整个医疗保健造成财务负担。一些大型医疗机构已经在努力解决这个问题,并开发了自己的测试利用管理方法。这些措施包括医生教育、提供测试定价信息、在计算机化供应商订单输入(CPOE)系统中使用提醒和/或设立委员会来授权使用昂贵或复杂的测试。虽然这些方法在抑制测试过度使用和产生成本节约方面取得了一些小的成功,但一个强大的自动化临床实验室决策支持系统仍然非常缺乏。我们提出,在这里,一个新开发的实验室决策系统,LDSTM作为一个潜在的方法来解决测试利用管理在临床设置。一项关于提供者和付款人使用LDSTM的研究表明,双方在测试订购和管理方面都有重大改善:提供者方面大幅减少了不必要的测试,付款人方面在医疗必要性检查方面有了可衡量的改善。减少浪费测试的方法。美国医师学会(American College of Physicians, ACP)在2012年发表的一份研究报告中解释说,“不必要的检查对医疗成本的影响每年高达2500亿美元”。该研究遏制了美国医疗保健领域过度治疗的趋势。医生需要及时、相关和可操作的数据,以便准确地安排检查,实验室和其他提供服务的机构也需要这些数据,以便有效地提供服务并及时获得报酬。此外,分子和基因检测(受欢迎的诊断和疾病管理新工具)的快速增长,对医疗保健提供者和商业付款人都提出了如何正确利用这些专门检测的挑战。鉴于其相对较高的成本,这些检测的不当使用对已经负担过重的医疗保健系统构成了额外的经济负担[2,4,5]。由于实验室检测提供了医生诊断和治疗所依据的70-85%的客观数据,因此实验室诊断已成为美国最大规模的医疗活动,估计每年进行40 - 50亿次检测。不适当的检测既包括过度利用,也包括利用不足,两者加起来会大大增加医疗保健成本。过度使用是指在没有临床指征的情况下订购的测试,而使用不足是指临床指征但未订购的测试。目前,医生们面临的挑战是无法获得关于数千种可用临床实验室测试的集中信息。共同财富基金对美国医疗保健系统公众意见的调查显示,医生要求的检查中,超过23%的人以前做过。这种重复增加了护理成本,同时进一步延迟或混淆了患者的诊断和护理[1,2]。2011年,美国疾病控制与预防中心(CDC)研究了医生对实验室适当利用的不确定性。这项研究调查了美国的1768名初级保健医生,结果表明14.7%的医生在选择和订购正确的检查时有不确定性,8.3%的医生在解释检查结果方面有困难。当这些统计数据应用于美国每年超过3亿患者的实验室访问时,不适当的测试顺序和解释每年可能影响2300万患者。这种不适当的测试使用对我们整个医疗保健系统有进一步的下游临床和成本影响。调查还表明,超过四分之三的受访医生表示,咨询专家、查看电子参考资料或专家推荐,有助于减少订购和解释实验室测试的不确定性。由于这些和其他令人信服的原因,支付方,特别是医疗保险,开始要求标准化的做法和Sci Forschen O . c . H . U . B . c . c . c . c . c . c .引用本文:Leblow L, Hamill t, Beqaj SH(2019)在临床环境中使用实验室决策系统作为测试利用管理工具,当前和未来的展望。临床检验医学4(1):dx.doi.org/10.16966/2572-9578.128 2《临床与检验医学开放获取杂志》年度荟萃分析显示,实验室检查的过度使用和不足使用分别占20.6%和44.8%[10]。不适当的检测可能导致不正确或延迟的诊断和治疗,从而对患者的恢复时间和相关成本产生负面影响。 长期以来,管理实验室测试的使用一直是医疗保健行业面临的一个日益严重的问题。随着检测数量的不断增加,特别是在每次检测成本非常高的分子遗传学领域,不适当的利用正在给整个医疗保健造成财务负担。一些大型医疗机构已经在努力解决这个问题,并开发了自己的测试利用管理方法。这些措施包括医生教育、提供测试定价信息、在计算机化供应商订单输入(CPOE)系统中使用提醒和/或设立委员会来授权使用昂贵或复杂的测试。虽然这些方法在抑制测试过度使用和产生成本节约方面取得了一些小的成功,但一个强大的自动化临床实验室决策支持系统仍然非常缺乏。我们提出,在这里,一个新开发的实验室决策系统,LDSTM作为一个潜在的方法来解决测试利用管理在临床设置。一项关于提供者和付款人使用LDSTM的研究表明,双方在测试订购和管理方面都有重大改善:提供者方面大幅减少了不必要的测试,付款人方面在医疗必要性检查方面有了可衡量的改善。减少浪费测试的方法。美国医师学会(American College of Physicians, ACP)在2012年发表的一份研究报告中解释说,“不必要的检查对医疗成本的影响每年高达2500亿美元”。该研究遏制了美国医疗保健领域过度治疗的趋势。医生需要及时、相关和可操作的数据,以便准确地安排检查,实验室和其他提供服务的机构也需要这些数据,以便有效地提供服务并及时获得报酬。此外,分子和基因检测(受欢迎的诊断和疾病管理新工具)的快速增长,对医疗保健提供者和商业付款人都提出了如何正确利用这些专门检测的挑战。鉴于其相对较高的成本,这些检测的不当使用对已经负担过重的医疗保健系统构成了额外的经济负担[2,4,5]。由于实验室检测提供了医生诊断和治疗所依据的70-85%的客观数据,因此实验室诊断已成为美国最大规模的医疗活动,估计每年进行40 - 50亿次检测。不适当的检测既包括过度利用,也包括利用不足,两者加起来会大大增加医疗保健成本。过度使用是指在没有临床指征的情况下订购的测试,而使用不足是指临床指征但未订购的测试。目前,医生们面临的挑战是无法获得关于数千种可用临床实验室测试的集中信息。共同财富基金对美国医疗保健系统公众意见的调查显示,医生要求的检查中,超过23%的人以前做过。这种重复增加了护理成本,同时进一步延迟或混淆了患者的诊断和护理[1,2]。2011年,美国疾病控制与预防中心(CDC)研究了医生对实验室适当利用的不确定性。这项研究调查了美国的1768名初级保健医生,结果表明14.7%的医生在选择和订购正确的检查时有不确定性,8.3%的医生在解释检查结果方面有困难。当这些统计数据应用于美国每年超过3亿患者的实验室访问时,不适当的测试顺序和解释每年可能影响2300万患者。这种不适当的测试使用对我们整个医疗保健系统有进一步的下游临床和成本影响。调查还表明,超过四分之三的受访医生表示,咨询专家、查看电子参考资料或专家推荐,有助于减少订购和解释实验室测试的不确定性。由于这些和其他令人信服的原因,支付方,特别是医疗保险,开始要求标准化的做法和Sci Forschen O . c . H . U . B . c . c . c . c . c . c .引用本文:Leblow L, Hamill t, Beqaj SH(2019)在临床环境中使用实验室决策系统作为测试利用管理工具,当前和未来的展望。临床检验医学4(1):dx.doi.org/10.16966/2572-9578.128 2《临床与检验医学开放获取杂志》年度荟萃分析显示,实验室检查的过度使用和不足使用分别占20.6%和44.8%[10]。不适当的检测可能导致不正确或延迟的诊断和治疗,从而对患者的恢复时间和相关成本产生负面影响。 检测的过度使用通常会增加假阳性结果的可能性,从而导致不正确的诊断、额外不适当的检测、成本增加以及由于无根据的干预而导致的不良结果[6,7]。此外,订购不经常指示的检查的后果可能是未能订购临床"指示"的检查,从而使问题进一步复杂化。由于诊断延迟或漏诊,检测利用不足可能导致发病率增加,而且矛盾的是,可能导致下游过度使用,再次导致更高的成本和更差的患者护理[2,7]。随着行业和政府从传统的收费服务转向基于价值的护理,过度/不足的利用是影响成本增加和临床结果不佳的底线的关键问题。为了实现现代医疗保健的目标,医疗提供者和保险支付者正在寻找有助于在选择诊断测试和确保适当利用实验室资源方面做出最佳决定的解决方案。目前解决测试利用问题的方法大型医疗机构已经做出了一些努力来解决测试利用问题。然而,值得列举的是影响订购行为的主要因素:CPOE订购的便利性、对测试特征的无知、同伴或主管要求极其彻底的压力、对诉讼的恐惧、不耐烦、对诊断确定性的渴望、经济激励和患者需求[2,5,8,9]。总的来说,对这些因素的全面管理需要新的工具、教育、习惯的改变和奖励反馈循环[8,10-12]。两项试图分析和解决测试使用问题的重要研究是退伍军人事务医院研究bbb和马萨诸塞州总医院(MGH)研究[8,14]。退伍军人事务医院的研究通过实施一个经过修改和改进的实验室信息系统来管理测试的使用,该系统允许他们设置特殊的规则、限制、提醒和通知,从而减少了不必要的测试,降低了成本。MGH的研究制定了一项实验室利用管理方案,要求委员会审查和批准测试订单,并充当“管理者”,防止从业者订购“不适当”的测试。这种方法的成本可想而知,因为它需要昂贵的专家(包括病理学家和遗传咨询师)“亲自”参与决策,而且不能及时做出反应[2,5,8,14]。负担过重的临床医生无法花费大量时间追踪病理学家,以获得他们通常需要立即得到的答案。其他几项研究使用了类似的策略来减少不必要的测试订购和降低成本,特别是在发送通常报销很少的测试方面,因此给许多小型和大型医院造成了财务负担[8,15,16]。临床决策支持系统选择合适的医学测试是一个持续存在和日益严重的问题,包括放射学、心脏病学、肺脏学和药理学。由于放射诊断成像比实验室测试更昂贵,美国政府已经批准了一项补偿奖励制度,用于利用临床决策支持系统(CDSS)来提高成像利用率,从而减少不必要的订单和成本。例如,2015年的《先进成像法案》(Advanced Imaging Bill)规定,只有在保险索赔确认咨询了适当使用标准或使用了CDSS的情况下,政府批准的成像服务才会得到报销[17,18]。该条例草案还建议,如有可能,在其他诊断测试订购中使用CDSS。因此,CDSS目前可用于心脏病学、药物管理、肿瘤学和泌尿学。这些发展强烈表明,实验室CDSS也有很大的需求,以帮助医疗保健提供者选择和订购实验室检测并减少不适当的检测[11,12]。目前,有一些部分开发和半手动的实验室CDSS,帮助医生订购实验室检查;然而,这些模块是由提供者驱动的,并且需要不方便的交互式用户问题来访问所需的信息[911,19,20]。此外,这些系统没有像放射科CDSS所使用的那样,为基于医学证据、临床相关性和医疗必要性的测试提供任何评分系统。为了应对这些挑战,Medical Database, Inc (MDB)开发了一个实验室决策支持平台,其中包括一个易于使用的测试订购和使用管理应用程序,也称为实验室决策系统或LDSTM。 检测的过度使用通常会增加假阳性结果的可能性,从而导致不正确的诊断、额外不适当的检测、成本增加以及由于无根据的干预而导致的不良结果[6,7]。此外,订购不经常指示的检查的后果可能是未能订购临床"指示"的检查,从而使问题进一步复杂化。由于诊断延迟或漏诊,检测利用不足可能导致发病率增加,而且矛盾的是,可能导致下游过度使用,再次导致更高的成本和更差的患者护理[2,7]。随着行业和政府从传统的收费服务转向基于价值的护理,过度/不足的利用是影响成本增加和临床结果不佳的底线的关键问题。为了实现现代医疗保健的目标,医疗提供者和保险支付者正在寻找有助于在选择诊断测试和确保适当利用实验室资源方面做出最佳决定的解决方案。目前解决测试利用问题的方法大型医疗机构已经做出了一些努力来解决测试利用问题。然而,值得列举的是影响订购行为的主要因素:CPOE订购的便利性、对测试特征的无知、同伴或主管要求极其彻底的压力、对诉讼的恐惧、不耐烦、对诊断确定性的渴望、经济激励和患者需求[2,5,8,9]。总的来说,对这些因素的全面管理需要新的工具、教育、习惯的改变和奖励反馈循环[8,10-12]。两项试图分析和解决测试使用问题的重要研究是退伍军人事务医院研究bbb和马萨诸塞州总医院(MGH)研究[8,14]。退伍军人事务医院的研究通过实施一个经过修改和改进的实验室信息系统来管理测试的使用,该系统允许他们设置特殊的规则、限制、提醒和通知,从而减少了不必要的测试,降低了成本。MGH的研究制定了一项实验室利用管理方案,要求委员会审查和批准测试订单,并充当“管理者”,防止从业者订购“不适当”的测试。这种方法的成本可想而知,因为它需要昂贵的专家(包括病理学家和遗传咨询师)“亲自”参与决策,而且不能及时做出反应[2,5,8,14]。负担过重的临床医生无法花费大量时间追踪病理学家,以获得他们通常需要立即得到的答案。其他几项研究使用了类似的策略来减少不必要的测试订购和降低成本,特别是在发送通常报销很少的测试方面,因此给许多小型和大型医院造成了财务负担[8,15,16]。临床决策支持系统选择合适的医学测试是一个持续存在和日益严重的问题,包括放射学、心脏病学、肺脏学和药理学。由于放射诊断成像比实验室测试更昂贵,美国政府已经批准了一项补偿奖励制度,用于利用临床决策支持系统(CDSS)来提高成像利用率,从而减少不必要的订单和成本。例如,2015年的《先进成像法案》(Advanced Imaging Bill)规定,只有在保险索赔确认咨询了适当使用标准或使用了CDSS的情况下,政府批准的成像服务才会得到报销[17,18]。该条例草案还建议,如有可能,在其他诊断测试订购中使用CDSS。因此,CDSS目前可用于心脏病学、药物管理、肿瘤学和泌尿学。这些发展强烈表明,实验室CDSS也有很大的需求,以帮助医疗保健提供者选择和订购实验室检测并减少不适当的检测[11,12]。目前,有一些部分开发和半手动的实验室CDSS,帮助医生订购实验室检查;然而,这些模块是由提供者驱动的,并且需要不方便的交互式用户问题来访问所需的信息[911,19,20]。此外,这些系统没有像放射科CDSS所使用的那样,为基于医学证据、临床相关性和医疗必要性的测试提供任何评分系统。为了应对这些挑战,Medical Database, Inc (MDB)开发了一个实验室决策支持平台,其中包括一个易于使用的测试订购和使用管理应用程序,也称为实验室决策系统或LDSTM。 该平台使医疗保健提供者能够访问系统和深入的资源,以帮助选择和订购最合适的实验室设备 该平台使医疗保健提供者能够访问系统和深入的资源,以帮助选择和订购最合适的实验室设备
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信